Diabetes mellitus and chronic kidney disease: achievements, unresolved problems, and prospects for therapy

被引:0
作者
Shestakova, M., V [1 ]
Shamkhalova, M. Sh [1 ]
Yarek-Martynova, I. Ya [1 ]
Klefortova, I. I. [1 ]
Sukhareva, O. Yu [1 ]
Vikulova, O. Yu [1 ]
Zaitseva, N., V [1 ]
Martynov, S. A. [1 ]
Kvaratskheliya, M., V [1 ]
Tarasov, E., V [1 ]
Trubitcyna, N. P. [1 ]
机构
[1] Endocrinol Res Ctr, Moscow, Russia
来源
DIABETES MELLITUS | 2011年 / 14卷 / 01期
关键词
diabetes mellitus; chronic kidney disease; diabetic nephropathy; renoprotection;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The dramatic increase in the number of patients with diabetes mellitus (DM) and chronic renal disease (CRD) in the recent years emphasizes the close association between the two conditions and the leading role of DM in the development of renal pathology. Diabetology and nephrology are highly costly branches of public health, and the burden of substitution renal therapy in DM patients continues to grow. The necessity of a renoprotection program at the early stages of DM for the prevention or delay of terminal renal insufficiency becomes increasingly clear. Such program should be based on the conceptual model of the evolvement of diabetic nephropathy as a consequence of combined action of metabolic and hemodynamic factors modulated by genetic ones.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 35 条
  • [1] Diabetic nephropathy: Linking histology, cell biology, and genetics
    Adler, S
    [J]. KIDNEY INTERNATIONAL, 2004, 66 (05) : 2095 - 2106
  • [2] Standards of Medical Care in Diabetes-2009
    不详
    [J]. DIABETES CARE, 2009, 32 : S13 - S61
  • [3] Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros, Vasilios G.
    Mikhailidis, Dimitri P.
    Kakafika, Anna I.
    Tziomalos, Konstantinos
    Karagiannis, Asterios
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (05) : 529 - 535
  • [4] Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction Of type 2 diabetes
    Brantsma, AH
    Bakker, SJL
    Hillege, HL
    De Zeeuw, D
    De Jong, PE
    Gansevoort, RT
    [J]. DIABETES CARE, 2005, 28 (10) : 2525 - 2530
  • [5] MOLECULAR-BASIS OF PROTEINURIA OF GLOMERULAR ORIGIN
    BRENNER, BM
    HOSTETTER, TH
    HUMES, HD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (15) : 826 - 833
  • [6] Brocco E, 1997, KIDNEY INT, pS40
  • [7] Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity
    Chao, Julie
    Li, Huey-Jiun
    Yao, Yu-Yu
    Shen, Bo
    Gao, Lin
    Bledsoe, Grant
    Chao, Lee
    [J]. HYPERTENSION, 2007, 49 (03) : 490 - 497
  • [8] Is kidney injury a reversible process?
    Chatziantoniou, Christos
    Dussaule, Jean-Claude
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (01) : 76 - 81
  • [9] Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor
    Costa-Scharplatz, Madlaina
    van Asselt, Antoinette D. I.
    Bachmann, Lucas M.
    Kessels, Alfons G. H.
    Severens, Johan L.
    [J]. PHARMACOGENETICS AND GENOMICS, 2007, 17 (05) : 359 - 368
  • [10] Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
    de Zeeuw, D
    Remuzzi, G
    Parving, HH
    Keane, WF
    Zhang, ZX
    Shahinfar, S
    Snapinn, S
    Cooper, MF
    Mitch, WE
    Brenner, BM
    [J]. KIDNEY INTERNATIONAL, 2004, 65 (06) : 2309 - 2320